Mercury Laboratories Ltd.
Snapshot View

746.00 ▼0%

26 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.mercurylabs.com
Financial Indicators
Market Cap 89.50 Cr.
Earnings per share (EPS) 44.48 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 16.77 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 307.46 Trailing Twelve Months Ending 2021-03
Price to Book Value 2.43 Calculated using Price: 745.85
Dividend Yield 0.47 Period Ending 2020-03
No. of Shares Subscribed 0.12 Cr. 1,200,000 Shares
FaceValue 10
Company Profile

Founded in 1962, Mercury laboratories began producing pharmaceutical products for mother and child health and subsequently introduced products in all dosage forms like tablets, capsules, liquids & injectables. 

For more than 5 decades, the company has been at the forefront of formulating, developing, marketing and distributing safe, innovative and cost-effective pharmaceuticals that help to improve the quality of life of patients. In so doing, they have delivered long-term, profitable returns to their investors, value to their partners and rewarding careers to their employees.

The company has maintained its leadership in its strong segments such as gynaec, cardio vascular, multivitamin & nutrition supplement, anti-biotic, pain management, and gastro.

The company’s international markets for pharmaceutical products now include several emerging country markets in Asia, Africa, Far east & part of regulated market. In the export markets, they had a great year with exponential growth, With 75 new registrations, they have expanded their reach to 20 countries.

Business area of the company:

The company is engaged in manufacturing of pharmaceutical products. It is mainly dedicated to Mother and child care products. 

Products:

• Paediatrics Segmentation
• Obstetrics & Gynaecology Segmentation
• Surgeon Segementation
• General segmentation

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
+3.61%
1 Month
+6.57%
3 Month
-15.01%
6 Month
+24.13%
1 Year
+136.45%
2 Year
+213.05%
5 Year
+62.88%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 25.59 22.62 23.18 19.75 19.62 11.67 7.92 10.26 10.59
Return on Capital Employed (%) 30.53 24.67 26.27 21.32 21.58 18.93 9.89 13.77 13.25
Return on Assets (%) 11.07 9.13 8.82 8.01 8.81 5.54 3.92 5.20 5.68

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 10 12 15 18 22 24 26 29 32
Non Curr. Liab. 3 9 5 4 4 10 12 11 9
Curr. Liab. 10 12 19 21 20 17 13 17 15
Minority Int.
Equity & Liab. 23 33 40 43 47 51 52 57 56
Non Curr. Assets 7 18 20 20 19 20 22 25 25
Curr. Assets 16 15 21 23 28 31 30 32 32
Misc. Exp. not W/O
Total Assets 23 33 40 43 47 51 52 57 56

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 27 33 41 41 48 48 52 56 57
Other Income 1 1 1 1 1 0 0 1 1
Total Income 27 34 42 42 48 48 52 57 58
Total Expenditure -24 -30 -35 -35 -41 -41 -47 -50 -51
PBIDT 4 5 7 7 7 7 5 7 7
Interest 0 0 -1 -1 -1 -1 -1 -1 -1
Depreciation 0 0 -1 -1 -1 -1 -1 -2 -2
Taxation -1 -1 -2 -1 -1 -2 0 -1 -1
Exceptional Items 0 0 0
PAT 2 3 3 3 4 3 2 3 3

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 3 7 3 3 0 2 5 5 5
Cash Fr. Inv. -3 -12 -2 -2 0 -2 -4 -5 -1
Cash Fr. Finan. 0 5 -1 -2 0 0 1 -3 -3
Net Change 1 1 0 0 0 0 2 -2 1
Cash & Cash Eqvt 1 1 1 1 1 1 4 1 3

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 73.62 73.62 73.62 73.62 73.62 73.62 73.62 73.66 73.66
Public 26.38 26.38 26.38 26.38 26.38 26.38 26.38 26.34 26.34
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Mercury Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Wed, 14 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Kinjal Khandelwal
Designation :- Company Secretary and Compliance Officer
Tue, 13 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Please find enclosed herewith certificate received by companys Registrar And Share Transfer Agent (RTA) Viz Link Intime India Pvt Ltd A SEBI Registered Category-I RTA bearing Registration Number INR000004058 confirming compliance with Regulation 74(5) of Securities Exchange Board of India (Depositories and Participants ) Regulations 2018


You are requested to take the above information on record.

Technical Scans View Details

Mon, 26 Jul 2021
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 697.05 -0.9%
Divi's Laboratories Ltd. 130,349.05 4,915.30 -0.1%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,339.35 -1.3%
Cipla Ltd. 76,675.40 942.25 -0.9%
Cadila Healthcare Ltd. 61,992.73 610.55 +0.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,094.00 -0.2%
Aurobindo Pharma Ltd. 55,837.02 950.25 -0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 697.05 -0.9%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,915.30 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,339.35 -1.3%
Cipla Ltd. Consolidated 2021-03 31.88 942.25 -0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 610.55 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,094.00 -0.2%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 950.25 -0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 697.05 -0.9%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,915.30 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,339.35 -1.3%
Cipla Ltd. Consolidated 2021-03 4.18 942.25 -0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 610.55 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,094.00 -0.2%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 950.25 -0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 697.05 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,915.30 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,339.35 -1.3%
Cipla Ltd. Consolidated 2020-03 0.18 942.25 -0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 610.55 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,094.00 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 950.25 -0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 697.05 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,915.30 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,339.35 -1.3%
Cipla Ltd. Consolidated 2020-03 10.09 942.25 -0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 610.55 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,094.00 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 950.25 -0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 697.05 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,915.30 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,339.35 -1.3%
Cipla Ltd. Consolidated 2020-03 12.53 942.25 -0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 610.55 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,094.00 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 950.25 -0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 697.05 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,915.30 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,339.35 -1.3%
Cipla Ltd. Consolidated 2020-03 17,131.99 942.25 -0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 610.55 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,094.00 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 950.25 -0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 697.05 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,915.30 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,339.35 -1.3%
Cipla Ltd. Consolidated 2020-03 1,546.98 942.25 -0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 610.55 +0.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,094.00 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 950.25 -0.3%